 Connection
Lisa Bero to Clinical Trials as Topic
This is a "connection" page, showing publications Lisa Bero has written about Clinical Trials as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
2.257 |
|
|
|
-
Lundh A, Bero L. The ties that bind. BMJ. 2017 Jan 17; 356:j176.
Score: 0.420
-
Krle?a-Jeri? K, Lemmens T, Reveiz L, Cuervo LG, Bero LA. Prospective registration and results disclosure of clinical trials in the Americas: a roadmap toward transparency. Rev Panam Salud Publica. 2011 Jul; 30(1):87-96.
Score: 0.286
-
Saint-Raymond A, Hill S, Martines J, Bahl R, Fontaine O, Bero L. CONSORT 2010. Lancet. 2010 Jul 24; 376(9737):229-30.
Score: 0.268
-
Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med. 2008 Nov 25; 5(11):e217; discussion e217.
Score: 0.239
-
White J, Parascandola M, Bero L. Tobacco industry research and protection of human subjects: a case study of R. J. Reynolds. Nicotine Tob Res. 2007 Nov; 9(11):1213-25.
Score: 0.222
-
Helfer B, Leonardi-Bee J, Mundell A, Parr C, Ierodiakonou D, Garcia-Larsen V, Kroeger CM, Dai Z, Man A, Jobson J, Dewji F, Kunc M, Bero L, Boyle RJ. Conduct and reporting of formula milk trials: systematic review. BMJ. 2021 10 13; 375:n2202.
Score: 0.146
-
Lexchin J, Bero LA, Davis C, Gagnon MA. Achieving greater independence from commercial influence in research. BMJ. 2021 03 09; 372:n370.
Score: 0.140
-
Rasmussen K, Bero L, Redberg R, G?tzsche PC, Lundh A. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ. 2018 Oct 03; 363:k3654.
Score: 0.118
-
Bero L, Rennie D. The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. JAMA. 1995 Dec 27; 274(24):1935-8.
Score: 0.098
-
Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, Thombs BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ. 2012 Aug 16; 345:e5155.
Score: 0.077
-
Hart B, Lundh A, Bero L. Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses. BMJ. 2012 Jan 03; 344:d7202.
Score: 0.074
-
Rattinger G, Bero L. Factors associated with results and conclusions of trials of thiazolidinediones. PLoS One. 2009 Jun 08; 4(6):e5826.
Score: 0.062
-
Elliott JH, Grimshaw J, Altman R, Bero L, Goodman SN, Henry D, Macleod M, Tovey D, Tugwell P, White H, Sim I. Informatics: Make sense of health data. Nature. 2015 Nov 05; 527(7576):31-2.
Score: 0.024
-
Chang L, Dhruva SS, Chu J, Bero LA, Redberg RF. Selective reporting in trials of high risk cardiovascular devices: cross sectional comparison between premarket approval summaries and published reports. BMJ. 2015 Jun 10; 350:h2613.
Score: 0.023
-
Dhruva SS, Bero LA, Redberg RF. Gender bias in studies for Food and Drug Administration premarket approval of cardiovascular devices. Circ Cardiovasc Qual Outcomes. 2011 Mar; 4(2):165-71.
Score: 0.017
-
Chen CE, Dhruva SS, Bero LA, Redberg RF. Inclusion of training patients in US Food and Drug Administration premarket approval cardiovascular device studies. Arch Intern Med. 2011 Mar 28; 171(6):534-9.
Score: 0.017
-
Dhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009 Dec 23; 302(24):2679-85.
Score: 0.016
-
Lexchin J, Bero LA, Djulbegovic B, Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ. 2003 May 31; 326(7400):1167-70.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|